CSB_UGent conducts natural product discovery and microbial production optimization to identify and upscale small molecules with antimicrobial properties. This involves genomics and metabolomics analysis, strain engineering, and metabolic optimization for enhanced production.
CSB_UGent offers a comprehensive solution for discovering and upscaling the production of natural antimicrobial small molecules. Collaborating with industrial partners, CSB_UGent utilizes advanced genomics and metabolomics analyses to identify novel molecules with potential antimicrobial activity. The process involves rigorous screening for antimicrobial efficacy against selected pathogens, followed by targeted strain engineering to enhance production.
This technology is currently at TRL 3, indicating experimental proof of concept has been achieved. Further validation and optimization are ongoing in collaboration with industrial partners to advance the technology to higher readiness levels.
Ghent University is a comprehensive public research university with a strong applied research and innovation culture. Industry collaborates through the Tech Lane Ghent Science Park, where corporate R&D, public research institutes and UGent labs are co‑located, and via a second science park in Ostend. Integration with Ghent University Hospital enables clinical translation and access to patient care environments. Research is backed by competitive European programmes such as Horizon Europe and the ERC, alongside national and regional support from FWO and VLAIO. UGent’s TechTransfer office, working with an Industrial Liaison Network and a central EU funding team, supports IP, licensing, spin‑offs and contract research to accelerate partnerships.